Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.
Talk to the deal team
Aenza S.A.A. has completed a follow-on
Aenza S.A.A. has completed af follow-on to prepay part of a recently renegotiated bridge loan.Learn more
move UP has been acquired by Acture B.V.
move UP Gesellschaft für Gesundheitsmanagement mbH, an innovative provider of holistic corporate health management solutions, has been acquired by Acture B.V., a leader in welfare management. This acquisition represents a major step in Acture’s plans to expand into the German corporate health management sector.Learn more
Pampa Camarones has completed an IPO
Pampa Camarones SpA has successfully raised US$5 million through its stock market debut on ScaleX (Santiago Venture Exchange). These funds will be used to extend the mine life and incorporate the high-grade polymetallic project, Ciclón Exploradora.Learn more